New Zealand - English - Medsafe (Medicines Safety Authority)

servier laboratories nz ltd - indapamide hemihydrate 0.625mg;  ; perindopril erbumine 2mg (erbumine = tert-butylamine salt);   - tablet - 0.625mg/2mg - active: indapamide hemihydrate 0.625mg   perindopril erbumine 2mg (erbumine = tert-butylamine salt)   excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate powdered cellulose - for the treatment of essential hypertension

New Zealand - English - Medsafe (Medicines Safety Authority)

servier laboratories nz ltd - indapamide hemihydrate 1.25mg;  ; perindopril erbumine 4mg;   - tablet - 1.25mg/4mg - active: indapamide hemihydrate 1.25mg   perindopril erbumine 4mg   excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose - for use in second-line therapy for the treatment of essential hypertension, where blood pressure has not been adequately controlled by monotherapy

Ireland - English - HPRA (Health Products Regulatory Authority)

ltt pharma limited - perindopril arginine indapamide - film coated tablet - 5/1.25 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

les laboratoires servier - perindopril tert-butylamine salt, indapamide - tablets - 4/1.25 mg/mg - ace inhibitors and diuretics

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium polystyrene sulfonate, quantity: 999.3 mg/g - powder - excipient ingredients: saccharin; vanillin - treatment of hyperkalaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - calcium polystyrene sulfonate, quantity: 999.3 mg/g - powder - excipient ingredients: vanillin; saccharin - calcium resonium is an ion-exchange resin. it is recommended for the treatment of hyperkalaemia associated with anuria and severe oliguria.,it is also used to treat hyperkalaemia in patients requiring dialysis and in patients on regular haemodialysis or on prolonged peritoneal dialysis.

Australia - English - Department of Health (Therapeutic Goods Administration)

polystyrene sulfonate - sodium -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

kck pharmaceutical industries sdn. bhd. - calcium polystyrene sulfonate -

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - sodium polystyrene sulfonate 99.934% (binding capacity 3.1meq/g);  ;   - powder for oral solution - 3.1 meq/g - active: sodium polystyrene sulfonate 99.934% (binding capacity 3.1meq/g)     excipient: saccharin sodium vanillin - treatament of hyperkalaemia.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - sodium polystyrene sulfonate - powder for oral or rectal suspension - 999.34mg/1gram